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Wil A. van Beers,e Gabrie¨lle A. Ponjee,e Hans M. Merkusf
Background Although some paternal components to the predisposition to pre-eclampsia have been dem-
onstrated recently, it is not known whether such paternal factors play a role to thrombophilia-related
perinatal mortality.
Objective To compare the paternal and maternal contribution to perinatal mortality.
Study design Data from a prospective registry of perinatal mortality in a Dutch healthcare region were used.
Between December 1999 and May 2000, the prevalence of thrombophilia was studied in 74 women with a
history of perinatal mortality (female cases) and 54 of their male partners (male cases). Seventy-one healthy
unrelated women after uneventful pregnancies only and 66 of their male partners were used as controls.
Setting Obstetric outpatient clinic in a regional hospital (Remierde Graaf Group, Deflt).
Methods Presence of various coagulation abnormalities, hyperhomocysteinaemia and anticardiolipins was
investigated.
Results The frequency of antithrombin deficiency (12% vs 0%), increased activated protein C (APC)
resistance (32% vs 6%), total protein S deficiency (11% vs 1%) and elevated factor VIII:C activity (43% vs
17%) was significantly higher in female cases compared with controls. In male cases, the frequency of
increased APC resistance was significantly higher compared with controls (22% vs 0%). In 30 of the 54
couples with a history of perinatal mortality, more than one thrombophilic abnormality was found (55%)
compared with 10 of the 62 control couples (17%).
Conclusion The risk of having thrombophilia is doubled in men who have fathered pregnancies which ended
in perinatal death as well as in the mothers of such pregnancies.
INTRODUCTION
The risk of perinatal mortality in the Western world is
0.5% to 1% of children with a birthweight over 500 g.1 This
may be lowered if risk factors can be detected and adequate
preventive measures are undertaken. Maternal thrombophilia
is such a risk factor and has been related to pregnancy-
associated thrombosis and pre-eclampsia, intrauterine
growth restriction, placental abruption, recurrent miscar-
riage and late fetal loss.2–10 As much as 65% of those
vascular complications may be associated with some form
of inherited or acquired thrombophilia.11,12
In previous studies, 80% of the carriers of a thrombo-
philic genetic defect who experienced ‘unexplained’ fetal
death demonstrated placental thrombosis, infarctions and
extensive perivillous fibrin deposition.10 In pre-eclampsia,
paternal as well as maternal genes, expressed in the fetus
and the trophoblast, may play a part.13 The aim of our
study was to investigate the prevalence of both maternal
and paternal thrombophilia in parents who experienced at
least one episode of perinatal mortality and compare it to
a control group of parents with uncomplicated preceding
pregnancies.
METHODS
During the decade of 1983 to 1992, a prospective reg-
istry of perinatal mortality was performed in the Dutch
healthcare region Delft–Westland–Oostland (DWO).14
All cases of perinatal death with a birthweight of 500 g
or more—according to the definition of the World Health
Organisation (WHO) for standard national perinatal death
figures15—were included into the study (N ¼ 239). The
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perinatal mortality rate of the region during that period
was 8.25 per thousand. The reliability of these perinatal
death figures was studied earlier and proved to be
adequate as over 99% of all cases were registered.16
Between December 1999 and May 2000, these wom-
en and their male partners were approached by mail. For
59 women, no recent address could be traced, no response
was obtained of another 70 and 36 women refused to
participate. This left 74 women (female cases) for further
study. The perinatal deaths were classified (Table 1)
according to the methods as described earlier.14 Seven
women experienced more than one perinatal death. Among
the male partners of these 74 women, 2 men recently died
of sudden heart death, 10 were divorced and 8 refused
participation, leaving 54 male partners (male cases) for
further study.
Seventy-one control women with year of birth between
1950 and 1970 and 66 of their partners were recruited
by advertisement as controls. They were included if they
had delivered no fetus with malformations, they had no
history of perinatal mortality or recurrent miscarriage
and were not pregnant at the time of the study. The
study was approved by the local medical–ethical com-
mittee and all women and their partners gave informed
consent.
Blood was collected by venipuncture between 8 and
10 a.m. in all women and partners after overnight fasting.
Citrated (0.105 M trisodiumcitrate) blood samples were
used for the analysis of protein C activity (PCAct), anti-
thrombin activity (AT) and factor VIII activity (F VIII:C),
total protein S antigen (PSAg) and free protein S antigen
(free PSAg) concentration, activated protein C resistance
(APC-R) as well as DNA analysis for thrombophilia-related
mutations: Factor V G1691A (F V Leiden), Prothrombin
G20210A and Methylenetetrahydrofolatereductase (MTHFR)
C677T.
EDTA blood samples were taken to measure homocys-
teine concentrations and plasma anticardiolipid IgG and
IgM antibodies (ACA-IgG, ACA-IgM). Blood samples
were immediately centrifuged at 2000g for 20 minutes,
snap frozen in small aliquots and stored at 80C.
All functional clotting assays were performed on an
Electra 1600C Automatic Coagulation Analyzer (Instru-
mentation Laboratory, Milan, Italy) PCAct and AT were
determined by chromogenic assays (Chromogenix, Milan,
Italy). F VIII:C was performed as a two-step clotting assay
using factor-deficient plasma of Dade Behring (Marburg,
Germany). Anticoagulant response to APC (APC-R) was
defined as the ratio of the clotting times obtained in the
presence and absence of APC (Coatest APC Resistance,
Chromogenix). APC-R was defined to be increased when
the sensitivity ratio (SR) was <1.8. PSAg was quantitated
with specific enzyme linked immunosorbent assays
(ELISA; Dakopatts Copenhagen, Denmark). Free PSAg
was separated from PS-C4BP complexes by precipitation
with PEG 2000. ACA-IgG and ACA-IgM plasma levels
were established by ELISA (Quanta lite ACA IgG and
IgM, Inova Diagnostics, Netherlands). For the determina-
tion of fasting plasma homocysteine levels, high perfor-
mance liquid chromatography (HPLC) technique was
used.
For the molecular diagnosis of F V Leiden, the pro-
thrombin G20210A mutant and the C677T MTHFR mu-
tation, DNA was isolated from blood by the QIAamp DNA
Blood Mini Kit (Qiagen, Hilden, Germany). Multiplex
PCR was performed by amplifying specific sequences
of Factor V (F V), prothrombin (F II) and MTHFR
genes by multiple primer sets. The PCR products were
simultaneously analysed by reverse hybridisation with
specific probes for FV Arg506Gln and FII G20210A
and C677T MTHFR on a Line Probe Assay (LiPA) in a
semi-automated assay.17
Data analysis was performed with the Statistical Pack-
age for Social Sciences for Windows, version 10.0 (SPSS,
Chicago, USA). Numerical data were summarised with
means and standard deviations, categorical data with num-
bers and percentages. Relative risks of perinatal death
associated with laboratory abnormalities were expressed
as odds ratios, with 95% confidence intervals according to
Woolf.18 Adjustment for putative confounders such as
age, parity and blood type was performed with uncondi-
tional logistic regression. The cutoff levels were the
reference values of the laboratory.
Table 1. Classification of perinatal death.
Classification of perinatal death Present study
(n ¼ 74)
Total study14
(N ¼ 239)
Infection 6 16
Placental pathology 46 127
Maternal immune system pathology
Blood type incompatibility 1 2
Congenital malformations 17 55
Complications of
immaturity/prematurity
4 20
Birth trauma – 2
Unclassifiable – 17
Total 74 239
Table 2. Population characteristics of women. Values are presented as
median [range] or n (%).
Characteristic Female
cases*
(n ¼ 74)
Female
controls
(n ¼ 71)
P OR
(95% CI)
Age 41 [32–56] 39 [27–50] 0.02
Parity 3 [2–7] 2 [2–4] <0.001
Oral contraceptive use 18 (24) 13 (18) 0.42 1.4 (0.6–3.2)
* Female cases are women with perinatal death 500 g.
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Table 3. Thrombophilic factors in men. Values are presented as n (%).
Thrombophilic factors Cutoff values Male cases
(n ¼ 54)
Male controls
(n ¼ 66)
P OR (95% CI)
AT <80% 5 (9) 1 (2) 0.09 6.5 (0.7–58)
APC-R SR < 1.8 12 (22) 0 (0) <0.001 n.e.*
PCAct <70% 0 (0) 1 (2) 1.00 n.e.*
Total PSAg <70% 1 (2) 0 (0) 0.45 n.e.*
Free PSAg <20% 0 (0) 0 (0) 1.00 n.e.*
F VIII:C >150% 12 (22) 13 (20) 0.82 1.1 (0.5–3)
Homocysteine >15 Amol/L 4 (7) 7 (11) 0.75 0.7 (0.2–2)
ACA-IgM >20 GPL 3 (6) 1 (2) 0.33 3.8 (0.4–37)
ACA-IgG >15 MPL 5 (9) 3 (5) 0.47 2.1 (0.5–9)
Prothrombin mutation 1 (2) 1 (2) 1.00 1.2 (0.8–20)
Factor V Leiden 4 (7) 1 (2) 0.17 5.2 (0.6–48)
MTHFR mutation
Heterozygote 30 (56) 34 (51)
Homozygote 5 (9) 3 (5)
0.36 1.4 (0.7–3)
No. of values outside the cutoff value#
None 22 (41) 45 (70) 0.01 1 (– )
1 23 (43) 14 (22) 0.01 1.0 (0.1–11)
2 8 (15) 3 (5) 0.01 3.3 (0.3–40)
3 1 (2) 2 (3) 0.01 5.3 (0.3–83)
* n.e. ¼ not estimable.
# In the controls there were two missing values.
Table 4. Thrombophilic factors in either women or men. Values are presented as n (%).
Thrombophilic factors Cutoff values Couples of cases
(n ¼ 54)
Couples of controls
(n ¼ 62)
P OR (95% CI)
AT <80% 11 (20) 1 (2) 0.001 15.3 (1.9–123)
APC-R SR < 1.8 22 (41) 4 (7) <0.001 9.6 (3.1–30)
PCAct <70% 1 (2) 1 (2) 1.00 1.1 (0.1–19)
Total PSAg <70% 8 (15) 1 (2) 0.01 10.4 (1.3–86)
Free PSAg <20% 2 (4) 0 (0) 0.22 n.e.*
F VIII:C >150% 28 (52) 21 (34) 0.09 2.1 (1.0–4)
Homocysteine >15 Amol/L 4 (7) 9 (15) 0.25 0.5 (0.1–2)
ACA-IgM >20 GPL 4 (7) 2 (3) 0.42 2.4 (0.4–13)
ACA-IgG >15 MPL 9 (17) 7 (12) 0.43 1.5 (0.5–5)
Prothrombin mutation 3 (6) 6 (10) 0.50 0.6 (0.1–2)
Factor V Leiden 81 (15) 81 (13) 0.79 1.2 (0.4–3)
MTHFR mutation
Heterozygote 37 (69) 34 (55)
Homozygote 7 (13) 12 (19)
0.38 1.5 (0.6–4)
No. of values outside the cutoff value$
None 8 (15) 27 (45) <0.001 n.e.*
1 16 (30) 23 (38)
2 12 (22) 6 (10)
3 12 (22) 3 (5)
4 5 (9) 1 (2)
5 1 (2) 0 (0)
1 One homozygote F V Leiden mutation.
* n.e. ¼ not estimable.
$ In the controls there were two missing values.
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RESULTS
The characteristics of the women in the study and con-
trol groups are presented in Table 2. Adjustment for age
led to similar results for all analyses. The use of oral con-
traceptives (OCs) was not significantly different between
the two groups. There was no difference in age between
the male cases (median 42, range 35–61) and the controls
(median 41, range 31–53).
The distribution of causes of perinatal death investigated
in this study was in accordance with the distribution in the
total group of 239 cases as described earlier (Table 1).14
The frequencies of AT deficiency, total PSAg deficiency,
elevated F VIII:C levels and increased APC-R were signif-
icantly higher in female cases compared with controls. In our
study, 62% of the female cases and 48% of the control
women had blood type non-O (P ¼ 0.09). Neither the
prevalence of PCAct deficiency, free PSAg deficiency,
hyperhomocysteinaemia, elevated ACA antibodies, F V
Leiden mutation, prothrombin mutation nor the MTHFR
mutation was significantly different between the two groups.
The percentage of women with one or more thrombo-
philic factor was 70% (51/73) compared with 30% (21/69)
in control women (Table 2). A subgroup analysis taking all
cases with perinatal mortality due to placental pathology
(acute–subacute) into account showed the same statistical
significance in all studied thrombophilic factors as in the
complete analysis of all cases (women).
In male cases, significantly more frequently increased
APC-R was found compared with controls. The differences
in the frequency of the other thrombophilia factors were not
significant. The percentage of the cases with a thrombo-
philic factor was 60% (32/54) compared with 30% (19/64)
in the controls. No difference was found in homozygous
MTHFR gene mutation between the cases and the controls
(9% vs 5%; Table 3).
If the results were analysed for couples (results of both
partners available and one anomaly in either parent), similar
results were found. The odds ratios of the couples were high
for abnormally low AT (odds ratio 15, 95% CI 1.9–123),
increased APC-R (OR 9.6, 95% CI 3–30) and low total
PSAg (OR 10, 95% CI 1.3–86; Table 4).
In 30 of the 54 couples with a history of perinatal death,
more than one thrombotic risk factor was found (55%)
compared with 10 of the 62 control couples (17%). We
found no difference in MTHFR gene mutation in couples of
cases compared with control couples (13% vs 19%; Table 4).
DISCUSSION
This study shows that the prevalence of thrombophilia is
doubled in both women and men with a history of perinatal
mortality. Previous studies that investigated paternal con-
tribution to perinatal death, however, found no contribution
of the father concerning thrombophilia. Our results should
be interpreted with caution for the following reasons: The
number of cases was relatively small and as the perinatal
mortality took place more than 10 years ago, many women
could not be traced. Nevertheless, we believe that this
group is representative for the whole group of 239 patients
as the distribution of causes of death was comparable. The
relatively small number of cases made us decide not to
exclude women using OC as there was no significant
difference between number of pill users in both groups.
Furthermore, if we compared the results in the 56 female
cases with the 58 controls, both not using OC, the same
differences were found. Preston et al.12 found no significant
difference in fetal mortality in women whose partners had
thrombophilia (n ¼ 311) compared with that of women
whose partners had no known thrombophilia (n ¼ 84). This
can be explained by the low frequency of fetal loss. Gris
et al.9 performed a case–control study similar to ours in
women and their partners with late fetal loss. They ex-
cluded thromboembolic events in the past for both men and
women. The absence of an effect of the paternal genotype
in that study may well have been the result of this exclusion
criterion as a relation between a history of thromboembolic
events and perinatal mortality is highly probable.
A paternal role in adverse pregnancy outcome was
suggested in a study showing an association between pre-
eclampsia and changing paternity.13 Esplin et al.19 found
evidence for paternal as well as maternal components of the
predisposition to pre-eclampsia. Zusterzeel20 found the
glutathione S-transferase Pi val105/ val105 genotype signif-
icantly more often in mothers and fathers in cases of pre-
eclampsia. In perinatal death, however, the contribution of
this mutation is still unclear.
The fact that some thrombophilic factors, such as F V
Leiden, are present in the fetus, that cannot be demonstrated
in the mother,21,22 also contributes to the concept of some
paternal influence on pregnancy outcome. For example, the
expression of genetic thrombophilia in the fetus may have
negative influences on the fetal and intervillous blood
circulation, causing vascular disturbances leading to fetal
death. However, this is hypothetic. Also, thrombosis in early
pregnancy may lead to disturbances in the microcirculation
of developing organ systems possibly leading to congenital
malformations in the fetus.
Despite a low prevalence in the normal population for
true heritable AT deficiency (0.02–0.17%),23 12% of the
female cases in our study had low AT levels. Elevated F
VIII:C levels are more frequently seen in the blood type
non-O.24 As the distribution of blood type non-O was
equally divided between cases and controls, this shows that
the association with high F VIII:C levels was pre-existent,
and not the result of post-event elevations. Increased APC
resistance was highly prevalent in the female cases, how-
ever, in only 7 of these 24 cases (29%) was F V Leiden
present and its frequency was not significantly different as
compared with that in controls. So in over 70% the in-
creased APC resistance was not explained by this mutation.
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Besides the F V Leiden mutation, however, also acquired
risk factors like increased F VIII:C, lupus anticoagulant and
OC use are known to induce APC resistance.25 This sug-
gests that acquired rather than heritable increased APC
resistance is related to perinatal death. Also, new still un-
discovered (genetic) clotting factors may play a role. This
is in accordance with the raised Factor VIII concentrations,
found in our study, as no difference could be demonstrated
in the use of OCs. Our findings concerning the prothrom-
bin mutation are not in accordance with studies in which
heterozygosity of this mutation has been related to late
fetal death.6,10
Our findings about the influence of the MTHFR gene
mutation are in accordance with the study of Gris et al.9
Heterozygosity for the MTHFR gene mutation may act as
an additional factor in the presence of other thrombophilic
defects as folate requirements are increased and folate
stores become partially depleted during pregnancy. It is
highly unlikely that folate supplementation was used in
the studied period, as in the period 1983–1992, the use of
periconceptional folic acid supplementation was not yet
recommended as a mass media campaign started in 1995.26
Hyperhomocysteinaemia is more often described in
cases of early pregnancy loss.4,6 This may be an explana-
tion for the fact that we did not find a relation to late fetal
and early neonatal loss in our study as pregnancy loss
already could have occurred in the first trimester.
The presence of more than one thrombophilic factor
was far more frequent in women with a history of peri-
natal death compared with control women (Table 5).
Combinations of thrombophilic factors like low AT, low
free PSAg, low PCAct, increased APC-R and the pres-
ence of ACAs are often found in relation to perinatal
mortality.9,11,12
Our findings of increased prevalences of thrombophilic
abnormalities in couples with a child who died perinatally
show that both parents may contribute to a hypercoagulable
state in both the fetus and the placenta, resulting in fetal
loss. As the distribution of causes of perinatal mortality in
the study group of 74 cases was comparable with the total
group of 239 cases, we conclude that thrombophilia in both
men and women is a risk factor for perinatal death. Results
of controlled trials are needed to assess the effectiveness of
interventions in thrombophilia screen-positive women. So
far only the benefit of combined anticoagulant therapy in
antiphospholipid antibodies syndrome is demonstrated.27
As long as no evidence-based primary preventive methods
are available, more intensive monitoring may be indicated
as a secondary preventive measure. In cases with a history
of perinatal mortality, the thrombophilic status of both
parents should be determined.
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